Tag: AML

A promising avenue is the targeting of CD37, a tetraspanin family member broadly expressed on malignant myeloid blasts but with limited expression on normal hematopoietic stem cells. Debio 1562M,** a second-generation novel antibody-drug conjugate (ADC) developed by Debiopharm, is designed to target CD37 and deliver a potent cytotoxic payload directly to tumor cells. Here, we review the preclinical development, mechanism of action, and therapeutic potential of Debio 1562M in AML and MDS.

Acute Myeloid Leukemia (AML) is a heterogeneous and highly aggressive hematologic malignancy characterized by a wide range of cytogenetic and molecular abnormalities that define distinct disease subgroups.

During the annual meeting for the American Association for Cancer Research (AACR) meeting held April 25 - 30, 2025 in Chicago, Illinois, Swiss-based Debiopharm presented comprehensive preclinical results for Debio 1562M (see ADC Drugmap) a next-generation Antibody-Drug Conjugate (ADC) targeting the cell surface glycoprotein CD37 being developed to be a potential first in class therapy in Acute Myeloid Leukemia (AML) and Myelodysplastic syndrome (MDS).

The U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BL-M11D1, an antibody-drug conjugate (ADC) binding CD33, a sialic acid-dependent cytoadhesion molecule and a member of the sialic acid-binding immunoglobulin (Ig)-like lectins (Siglecs), which is a subset of the immunoglobulin superfamily molecules.

Results from a preclinical toxicity evaluation study with BVX001, a novel antibody-drug conjugates (ADC) being developed by BiVictriX, showed positive in vivo data when compared to gemtuzumab ozogamicin (Mylotarg™; Pfizer).

Magenta Therapeutics Halts Phase 1/2 Dose Escalation Trial of Conditioning ADC MGTA-117

Initial safety and efficacy findings from an open-label, dose-escalation and expansion cohorts of the Phase 1b/2 study of pivekimab sunirine (IMGN632), a CD123 (Interleukin-3 alpha...

Enrollment of the Phase 3 SIERRA trial of the Antibody-radiation Conjugate (ARC) 131I apamistamab (Iomab-B), being developed by Actinium Pharmaceuticals, has been completed. Iomab-B includes...

Presentations during the virtual 62nd American Society of Hematology (ASH) Annual Meeting for the ongoing Phase 1 dose-escalation clinical trial with STRO-001, a CD74-targeted...

The University of Minnesota's Institutional Review Board (IRB) and Cancer Protocol Review Committee (CPRC) has granted GT Biopharma (Westlake Village, CA 91362), permission to...